Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has cleared for the previously announced collaboration and license agreement between Akeso and Summit Therapeutics (the...
Longevity Biomedical, Inc. and Denali Capital Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity
Longevity Biomedical is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population. Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair. Total...
Optimum Nutrition® Believes There’s More of You in You
New Global Communication Platform Launches in More than 90 Markets Worldwide DOWNERS GROVE, Ill., Jan. 26, 2023 /PRNewswire/ -- Optimum Nutrition®, the world's number one sports nutrition brand,1 is excited to announce the launch of its new global communications platform 'There's more of you in you' in over 90 markets around...
Esaote presents the world premiere of its new MyLab™X90 ultrasound device
An innovative premium system combining outstanding performance with artificial intelligence to optimize workflows and support advanced and interconnected healthcare systems MANAMA, Bahrain, Jan. 26, 2023 /PRNewswire/ -- Today Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical IT– presents the world premiere of MyLab™X90, its...
Alma, a Sisram Medical company, announces the launch of Alma Duo – an advanced, FDA and CE approved solution that promotes sexual wellness for men and women
NURNBERG, Germany, Jan. 26, 2023 /PRNewswire/ -- Alma, one of the top three global leaders of energy-based medical and aesthetics solutions, has announced the launch of its new sexual wellness product - Alma Duo. Alma Duo is an advanced, safe, non-invasive and effective solution causing no pain, that enables patients to bring back spontaneity into their...
Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed by The Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2022. This year, Fosun International was accredited with the Platinum Award by The Asset for the first time...
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
First Generic of Abraxane in Korea, World 4th Commercial Scale-Up Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea, Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEO Jang Doo-hyun) signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer...
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit Further developments are planned to conduct with a licensing/collaboration partner BOSTON and SEOUL, Korea, Jan. 26, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com)...
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), with the lead candidate currently in IND-enabling stage. HBMAT was founded on the...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted to Colombia, Vietnam, and Saudi Arabia NDA submissions in 11 countries completed in the shortest time among K-pharma new drugs... accelerating expansions into...
